- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 25.11. | Day One Biopharmaceuticals stock maintains Buy rating at H.C. Wainwright | 5 | Investing.com | ||
| 25.11. | Day One Biopharmaceuticals: H.C. Wainwright bekräftigt "Buy"-Rating mit hohem Kursziel | 6 | Investing.com Deutsch | ||
| 13.11. | Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout | 5 | Benzinga.com | ||
| 13.11. | Mersana Catapults 200% On Day One Bio's Surprise Buyout | 9 | Investor's Business Daily | ||
| 13.11. | Mersana Therapeutics To Be Acquired By Day One Biopharmaceuticals For Up To $285 Mln | 12 | RTTNews | ||
| 13.11. | Day One Biopharmaceuticals to buy Mersana Therapeutics for $25/share upfront | 3 | Seeking Alpha | ||
| 13.11. | Day One Biopharmaceuticals to acquire Mersana Therapeutics in deal worth up to $285 million | 15 | Investing.com | ||
| 13.11. | Day One Biopharmaceuticals, Inc.: Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases | 384 | GlobeNewswire (Europe) | Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid... ► Artikel lesen | |
| 13.11. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | Day One Biopharmaceuticals raises 2025 revenue guidance to $145M-$150M as OJEMDA sees sustained double-digit growth | 4 | Seeking Alpha | ||
| 05.11. | Day One Biopharmaceuticals Q3 2025 slides: OJEMDA drives 15% revenue growth, guidance raised | 8 | Investing.com | ||
| 04.11. | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 04.11. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10. | Day One Biopharmaceuticals, Inc.: Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025 | 16 | GlobeNewswire (USA) | ||
| 10.10. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.08. | Day One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate | 8 | Seeking Alpha | ||
| 05.08. | Day One Biopharmaceuticals: Umsatzwachstum bei OJEMDA hält an, während die Entwicklungspipeline voranschreitet | 20 | Investing.com Deutsch | ||
| 05.08. | Day One Biopharmaceuticals Non-GAAP EPS of -$0.29 beats by $0.05, revenue of $33.91M misses by $0.99M | 17 | Seeking Alpha | ||
| 05.08. | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 05.08. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,85 | +0,06 % | BioNTech SE: Erste Ergebnisse aus BioNTechs und BMS' globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs | Zwischenergebnisse der globalen klinischen Phase-2-Studie bei lokal fortgeschrittenem/metastasiertem dreifach negativem Brustkrebs (triple-negative breast cancer, "TNBC") zeigten eine ermutigende Anti-Tumor-Aktivität... ► Artikel lesen | |
| CUREVAC | 4,270 | -0,84 % | Wochenend-Update: Curevac-Aktie im Fokus - was Anleger jetzt wissen müssen! | ||
| AMGEN | 268,60 | -0,79 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,602 | +0,02 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| BIOGEN | 148,20 | -0,10 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| CRISPR THERAPEUTICS | 47,400 | -1,66 % | CRISPR Therapeutics stock rating reiterated at Market Outperform by Citizens | ||
| MAINZ BIOMED | 1,040 | -0,95 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 32,110 | +1,73 % | Viking Therapeutics-Aktie: Was kommt 2026? | Kurz vor Jahresende nehmen wir die Aktie von Viking Therapeutics noch einmal unter die Lupe, denn das Unternehmen steht vor einem entscheidenden Jahr für seine Adipositas-Pipeline. Zwar sind keine Zulassungsentscheidungen... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,800 | +1,46 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 59,50 | -1,65 % | Tempus AI's Strategic Push to Expand Beyond Oncology | ||
| BIOCRYST PHARMACEUTICALS | 6,274 | -2,79 % | XFRA BO1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOCRYST PHARMAC.... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,340 | -0,03 % | Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing | ||
| BIOMARIN PHARMACEUTICAL | 45,000 | -0,88 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| EXELIXIS | 35,150 | +0,98 % | Exelixis stock holds steady as Stifel maintains $43 price target | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,855 | +2,50 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen |
Das Unternehmen DAY ONE BIOPHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 8,360 Euro und damit -0,71 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAY ONE BIOPHARMACEUTICALS INC finden Sie auf Wallstreet Online.